Abstract
Gene amplification is frequently present in human tumors, although specific target genes relevant to many amplified loci remain unidentified. An expression cloning assay enabled identification of a candidate oncogene derived from human chromosome 3p14.1. The cDNA retrieved from morphologically transformed cells contained the full-length protein coding region and detected an abundant transcript in the same cells. Sequence analysis revealed identity with the wild-type sequence of p44S10, a highly conserved subunit of the 26S proteasome that exhibits similarity to the Arabidopsis fus6/cop11 family of signaling molecules. p44S10 gene copy number and mRNA expression were increased in association with segmental 1.8–11-fold chromosomal gains in cutaneous malignant melanoma cell lines (5/13; 40%) and tumors (2/40; 5%), and in breast cancer MCF-7 cells. Likewise, malignant progression of human radial growth phase WM35 melanoma cells was associated with amplification and increased expression of endogenous p44S10, and increased expression of p44S10 was sufficient to induce proliferation of WM35 cells in vivo. The results demonstrate segmental copy number gains within chromosome 3p in cutaneous malignant melanoma and suggest that deregulation of a proteasome regulatory particle subunit may contribute to the malignant phenotype.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM and Meltzer PS . 1997 Science 277: 965–968
Bani MR, Rak J, Adachi D, Wiltshire R, Trent JM, Kerbel RS and Ben-David Y . 1996 Cancer Res 56: 3075–3086
Bardenheuer W, Michaelis S, Lux A, Vieten L, Brocker F, Julicher K, Willers C, Siebert R, Smith DI, van der Hout AH, Buys C, Schutte J and Opalka B . 1996 Genome Res 6: 176–186
Barks JH, Thompson FH, Taetle R, Yang JM, Stone JF, Wymer JA, Khavari R, Guan XY, Trent JM, Pinkel D and Nelson MA . 1997 Genes, Chrom Cancer 19: 278–285
Barnes WM . 1994 Proc Natl Acad Sci USA 91: 2216–2220
Bastian BC, LeBoit PE, Hamm H, Brocker EB and Pinkel D . 1998 Cancer Res 58: 2170–2175
Chamovitz DA, Wei N, Osterlund MT, von Arnim AG, Staub JM, Matsui M and Deng XW . 1996 Cell 86: 115–121
Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR and Chow LT . 1995 Genes Dev 9: 2335–2349
Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, Horner II JW and Depinho RA . 1997 Genes Dev 11: 2822–2834
Chomczynski P and Sacchi N . 1987 Anal Biochem 162: 156–159
Coux O, Tanaka K and Goldberg AL . 1996 An Rev Biochem 65: 801–847
Deshane J, Loechel F, Conry RM, Siegal GP, King CR and Curiel DT . 1994 Gene Therapy 1: 332–337
Dubiel W, Ferrell K and Rechsteiner M . 1995 Mol Biol Reports 21: 27–34
Foster KW, Ren S, Louro ID, Lobo-Ruppert SM, McKie-Bell P, Grizzle W, Hayes MR, Broker TR, Chow LT and Ruppert JM . 1999 Cell Growth Differ 10: 423–434
Glickman MH, Rubin DM, Coux O, Wefes I, Pfeifer G, Cjeka Z, Baumeister W, Fried VA and Finley D . 1998a Cell 94: 615–623
Glickman MH, Rubin DM, Fried VA and Finley D . 1998b Mol Cell Biol 18: 3149–3162
Guan X-Y, Meltzer PS, Dalton WS and Trent JM . 1994 Nat Genet 8: 155–161
Hochstrasser M . 1996 Ann Rev Genet 30: 405–439
Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW and Waldman FM . 1994 Proc Natl Acad Sci USA 91: 2156–2160
King RW, Deshaies RJ, Peters JM and Kirschner MW . 1996 Science 274: 1652–1659
Kolligs FT, Hu G, Dang CV and Fearon ER . 1999 Mol Cell Biol 19: 5696–5706
Montgomery DM . 1991 Design and analysis of experiments New York John Wiley & Sons
Neubauer A, Neubauer B, He M, Effert P, Iglehart D, Frye RA and Liu E . 1992 Oncogene 7: 1019–1025
Pear WS, Nolan GP, Scott ML and Baltimore D . 1993 Proc Natl Acad Sci USA 90: 8392–8396
Ruppert JM, Kinzler KW, Wong AJ, Bigner SH, Kao F-T, Law ML, Seuanez HN, O'Brien SJ and Vogelstein B . 1988 Mol Cell Biol 8: 3104–3113
Ruppert JM, Vogelstein B and Kinzler KW . 1991 Mol Cell Biol 11: 1724–1728
Schuler GD, Boguski MS, Stewart EA, Stein LD, Gyapay G, Rice K, White RE, Rodriguez-Tome P, Aggarwal A, Bajorek E, Bentolila S, Birren BB, Butler A, Castle AB, Chiannilkulchai N, Chu A, Clee C, Cowles S, Day PJ, Dibling T, Drouot N, Dunham I, Duprat S, East C, Hudson TJ et al. 1996 Science 274: 540–546
Seeger M, Kraft R, Ferrell K, Bech-Otschir D, Dumdey R, Schade R, Gordon C, Naumann M and Dubiel W . 1998 FASEB J 12: 469–478
Sozzi G, Huebner K and Croce CM . 1998 Adv Cancer Res 74: 141–166
Vogelstein B and Kinzler KW . 1998 The genetic basis of human cancer New York McGraw-Hill
Wong AJ, Ruppert JM, Eggleston J, Hamilton SR, Baylin SB and Vogelstein B . 1986 Science 233: 461–464
Acknowledgements
Tissue was obtained through the Tissue Procurement Facility of the University of Alabama at Birmingham Comprehensive Cancer Center and the Cooperative Human Tissue Network. Funded by NIH grants R29CA65686 (JM Ruppert) and CA48031 (N-d Wang and DI Smith), a Jr. Faculty Award through the Comprehensive Cancer Center (JMR), and grants from the Medical Research Council of Canada (Y Ben-David).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ren, S., Smith, M., Louro, I. et al. The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. Oncogene 19, 1419–1427 (2000). https://doi.org/10.1038/sj.onc.1203462
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203462
Keywords
This article is cited by
-
Proteasome dysregulation in human cancer: implications for clinical therapies
Cancer and Metastasis Reviews (2017)
-
Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity
Oncogene (2013)
-
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)
Oncogene (2009)
-
An integrated analysis of genes and pathways exhibiting metabolic differences between estrogen receptor positive breast cancer cells
BMC Cancer (2007)